Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

Silvio Danese; Gionata Fiorino; Pierre Michetti

doi:10.1016/j.crohns.2014.06.007

Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

Silvio Danese, Gionata Fiorino, Pierre Michetti

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.

Original language	English
Pages (from-to)	1548-1550
Number of pages	3
Journal	Journal of Crohn's & colitis
Volume	8
Issue number	11
DOIs	https://doi.org/10.1016/j.crohns.2014.06.007
Publication status	Published - 2014

Keywords

Biosimilar
ECCO
Inflammatory bowel disease
Monoclonal

ASJC Scopus subject areas

Gastroenterology
Medicine(all)

Access to Document

10.1016/j.crohns.2014.06.007

Fingerprint Dive into the research topics of 'Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization'. Together they form a unique fingerprint.

Cite this

@article{eec83c244200488ca6da179ac49113b8,

title = "Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization",

abstract = "Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.",

keywords = "Biosimilar, ECCO, Inflammatory bowel disease, Monoclonal",

author = "Silvio Danese and Gionata Fiorino and Pierre Michetti",

year = "2014",

doi = "10.1016/j.crohns.2014.06.007",

language = "English",

volume = "8",

pages = "1548--1550",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Viewpoint

T2 - Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

AU - Danese, Silvio

AU - Fiorino, Gionata

AU - Michetti, Pierre

PY - 2014

Y1 - 2014

N2 - Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.

AB - Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.

KW - Biosimilar

KW - ECCO

KW - Inflammatory bowel disease

KW - Monoclonal

UR - http://www.scopus.com/inward/record.url?scp=84929610400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929610400&partnerID=8YFLogxK

U2 - 10.1016/j.crohns.2014.06.007

DO - 10.1016/j.crohns.2014.06.007

M3 - Article

C2 - 25008477

AN - SCOPUS:84929610400

VL - 8

SP - 1548

EP - 1550

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 11

ER -